MIST - Milestone Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

Canada NewsWire

MONTREAL and CHARLOTTE, N.C. , May 17, 2022 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto , President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference being held on May 23-26, 2022 .

The pre-recorded fireside chat will become available on Tuesday, May 24, 2022 at 7:00am ET and can be accessed in the News & Events section of Milestone's website at www.milestonepharma.com . An archived replay of the presentation will be available on the same website for approximately 90 days following the presentation.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), is a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines. Milestone's lead product candidate etripamil is currently in a Phase 3 clinical-stage program for the treatment of paroxysmal supraventricular tachycardia (PSVT) and in a Phase 2 proof-of-concept trial for the treatment of patients with atrial fibrillation with rapid ventricular rate (AFib-RVR). Milestone Pharmaceuticals operates in Canada and the United States . For more information, visit www.milestonepharma.com and follow Milestone on Twitter at @MilestonePharma.

Contact

David Pitts
Argot Partners
212-600-1902
david@argotpartners.com

SOURCE Milestone Pharmaceuticals, Inc.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/May2022/17/c5093.html